Literature DB >> 8441397

Nonimmune thyroid destruction results from transgenic overexpression of an allogeneic major histocompatibility complex class I protein.

A G Frauman1, P Chu, L C Harrison.   

Abstract

The overexpression of major histocompatibility complex (MHC) class I molecules in endocrine epithelial cells is an early feature of autoimmune thyroid disease and insulin-dependent diabetes mellitus, which may reflect a cellular response, e.g., to viruses or toxins. Evidence from a transgenic model in pancreatic beta cells suggests that MHC class I overexpression could play an independent role in endocrine cell destruction. We demonstrate in this study that the transgenic overexpression of an allogeneic MHC class I protein (H-2Kb) linked to the rat thyroglobulin promoter, in H-2Kk mice homozygous for the transgene, leads to thyrocyte atrophy, hypothyroidism, growth retardation, and death. Thyrocyte atrophy occurred in the absence of lymphocytic infiltration. Tolerance to allogeneic class I was revealed by the reduced ability of primed lymphocytes from transgenic mice to lyse H-2Kb target cells in vitro. This nonimmune form of thyrocyte destruction and hypothyroidism recapitulates the beta-cell destruction and diabetes that results from transgenic overexpression of MHC class I molecules in pancreatic beta cells. Thus, we conclude that overexpression of MHC class I molecules may be a general mechanism that directly impairs endocrine epithelial cell viability.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8441397      PMCID: PMC359467          DOI: 10.1128/mcb.13.3.1554-1564.1993

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  38 in total

Review 1.  A molecular model of MHC class-I-restricted antigen processing.

Authors:  J J Monaco
Journal:  Immunol Today       Date:  1992-05

2.  HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides.

Authors:  M L Wei; P Cresswell
Journal:  Nature       Date:  1992-04-02       Impact factor: 49.962

3.  Dysmyelination in transgenic mice resulting from expression of class I histocompatibility molecules in oligodendrocytes.

Authors:  A M Turnley; G Morahan; H Okano; O Bernard; K Mikoshiba; J Allison; P F Bartlett; J F Miller
Journal:  Nature       Date:  1991-10-10       Impact factor: 49.962

4.  Multiple sclerosis. The case of the wonky mouse.

Authors:  P Parham
Journal:  Nature       Date:  1991-10-10       Impact factor: 49.962

5.  Linkage of faulty major histocompatibility complex class I to autoimmune diabetes.

Authors:  D Faustman; X P Li; H Y Lin; Y E Fu; G Eisenbarth; J Avruch; J Guo
Journal:  Science       Date:  1991-12-20       Impact factor: 47.728

6.  De novo HLA class II and enhanced HLA class I molecule expression in SV40 transfected human thyroid epithelial cells.

Authors:  A Belfiore; T Mauerhoff; R Pujol-Borrell; K Badenhoop; M Buscema; R Mirakian; G F Bottazzo
Journal:  J Autoimmun       Date:  1991-06       Impact factor: 7.094

7.  Autoimmune diabetes as a consequence of locally produced interleukin-2.

Authors:  W R Heath; J Allison; M W Hoffmann; G Schönrich; G Hämmerling; B Arnold; J F Miller
Journal:  Nature       Date:  1992-10-08       Impact factor: 49.962

8.  Diabetes in transgenic mice resulting from over-expression of class I histocompatibility molecules in pancreatic beta cells.

Authors:  J Allison; I L Campbell; G Morahan; T E Mandel; L C Harrison; J F Miller
Journal:  Nature       Date:  1988-06-09       Impact factor: 49.962

9.  Effects of recombinant human interleukin-2 and tumor necrosis factor-alpha with or without interferon-gamma on human thyroid tissues from patients with Graves' disease and from normal subjects xenografted into nude mice.

Authors:  Y Kasuga; S Matsubayashi; F Akasu; N Miller; C Jamieson; R Volpé
Journal:  J Clin Endocrinol Metab       Date:  1991-06       Impact factor: 5.958

10.  Efficient dissociation of the p88 chaperone from major histocompatibility complex class I molecules requires both beta 2-microglobulin and peptide.

Authors:  E Degen; M F Cohen-Doyle; D B Williams
Journal:  J Exp Med       Date:  1992-06-01       Impact factor: 14.307

View more
  6 in total

1.  Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies.

Authors:  K Nagaraju; N Raben; L Loeffler; T Parker; P J Rochon; E Lee; C Danning; R Wada; C Thompson; G Bahtiyar; J Craft; R Hooft Van Huijsduijnen; P Plotz
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

2.  Transcriptional regulation of HLA-A and -B: differential binding of members of the Rel and IRF families of transcription factors.

Authors:  J Girdlestone; M Isamat; D Gewert; C Milstein
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

3.  HLA-B35 upregulates endothelin-1 and downregulates endothelial nitric oxide synthase via endoplasmic reticulum stress response in endothelial cells.

Authors:  Stefania Lenna; Danyelle M Townsend; Filemon K Tan; Bagrat Kapanadze; Malgorzata Markiewicz; Maria Trojanowska; Raffaella Scorza
Journal:  J Immunol       Date:  2010-03-24       Impact factor: 5.422

4.  Self-reactive B cells are not eliminated or inactivated by autoantigen expressed on thyroid epithelial cells.

Authors:  S Akkaraju; K Canaan; C C Goodnow
Journal:  J Exp Med       Date:  1997-12-15       Impact factor: 14.307

5.  Transforming growth factor beta 1 (TGF-beta 1) controls expression of major histocompatibility genes in the postnatal mouse: aberrant histocompatibility antigen expression in the pathogenesis of the TGF-beta 1 null mouse phenotype.

Authors:  A G Geiser; J J Letterio; A B Kulkarni; S Karlsson; A B Roberts; M B Sporn
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

6.  In vivo expression of MHC class I genes depends on the presence of a downstream barrier element.

Authors:  Helit Cohen; Palak Parekh; Zeynep Sercan; Aparna Kotekar; Jocelyn D Weissman; Dinah S Singer
Journal:  PLoS One       Date:  2009-08-26       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.